Trevi Therapeutics, Inc. (NASDAQ:TRVI) Shares Sold by XTX Topco Ltd

XTX Topco Ltd decreased its position in shares of Trevi Therapeutics, Inc. (NASDAQ:TRVI) by 84.6% during the 1st quarter, according to its most recent disclosure with the SEC. The firm owned 10,380 shares of the company’s stock after selling 56,821 shares during the period. XTX Topco Ltd’s holdings in Trevi Therapeutics were worth $65,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also modified their holdings of the company. Summit Investment Advisors Inc. lifted its stake in shares of Trevi Therapeutics by 84.2% during the fourth quarter. Summit Investment Advisors Inc. now owns 6,332 shares of the company’s stock valued at $26,000 after buying an additional 2,894 shares during the period. Raymond James Financial Inc. purchased a new position in shares of Trevi Therapeutics during the fourth quarter valued at approximately $49,000. Squarepoint Ops LLC purchased a new position in shares of Trevi Therapeutics during the fourth quarter valued at approximately $58,000. Two Sigma Advisers LP purchased a new position in shares of Trevi Therapeutics during the fourth quarter valued at approximately $66,000. Finally, Cantor Fitzgerald L. P. purchased a new position in shares of Trevi Therapeutics during the fourth quarter valued at approximately $82,000. Hedge funds and other institutional investors own 95.76% of the company’s stock.

Wall Street Analyst Weigh In

Several equities analysts recently issued reports on TRVI shares. Oppenheimer reissued an “outperform” rating on shares of Trevi Therapeutics in a research note on Monday, June 2nd. Raymond James Financial reduced their price objective on shares of Trevi Therapeutics from $29.00 to $27.00 and set a “strong-buy” rating on the stock in a research note on Friday, August 8th. D. Boral Capital reaffirmed a “buy” rating and set a $21.00 price target on shares of Trevi Therapeutics in a research note on Monday, June 2nd. Cantor Fitzgerald began coverage on shares of Trevi Therapeutics in a research note on Tuesday, July 1st. They set an “overweight” rating and a $25.00 price target on the stock. Finally, Needham & Company LLC cut their price target on shares of Trevi Therapeutics from $24.00 to $22.00 and set a “buy” rating on the stock in a research note on Friday, August 8th. One analyst has rated the stock with a sell rating, seven have assigned a buy rating and three have given a strong buy rating to the stock. According to MarketBeat.com, Trevi Therapeutics currently has an average rating of “Buy” and an average target price of $20.38.

Trevi Therapeutics Stock Up 0.4%

Trevi Therapeutics stock opened at $7.52 on Friday. Trevi Therapeutics, Inc. has a 52-week low of $2.36 and a 52-week high of $8.11. The firm has a fifty day moving average of $6.67 and a 200-day moving average of $6.04. The firm has a market capitalization of $915.79 million, a P/E ratio of -17.90 and a beta of 0.58.

Trevi Therapeutics (NASDAQ:TRVI) last released its quarterly earnings data on Thursday, August 7th. The company reported ($0.09) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.10) by $0.01. On average, research analysts expect that Trevi Therapeutics, Inc. will post -0.49 EPS for the current fiscal year.

About Trevi Therapeutics

Trevi Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapy Haduvio for the treatment of chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC) conditions targeting the central and peripheral nervous systems.